Quantcast
Last updated on April 19, 2014 at 7:21 EDT

Sosei Announces Initiation of Phase I Study for SO-1105

March 8, 2012

TOKYO, March 8, 2012 /PRNewswire/ –

Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), the biopharmaceutical
company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has
initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal
candidiasis. SO-1105 was originally developed by a French pharmaceutical company,
BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France
in October 2006. SO-1105 has since been registered in 26 European countries, in South
Korea, and in the United States, under the trade names Loramyc(R)/Oravig(R).

The clinical study will be conducted in a single study centre in Japan, and is
designed to evaluate the pharmacokinetics and safety of SO-1105 in healthy Japanese
adults.

SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the
treatment of oropharyngeal candidiasis in immunocompromised patients. SO-1105 has the
potential to become the first long-acting, sustained-release treatment in tablet form for
oropharyngeal candidiasis in Japan that could enhance patients’ compliance and quality of
life.

Shinichi Tamura, CEO of Sosei Group Corporation, commented: “This is an important step
forward in development of SO-1105. We will continue with our efforts to bring SO-1105 to
the Japanese market, as it has the potential to provide meaningful benefits to OPC
patients compared to existing treatments.”

Notes for Editors:

About Oropharyngeal Candidiasis

Fungal infections of the oral mucosa are most frequently caused by Candida species,
with C. albicans being the most common species associated with such infections.
Oropharyngeal candidiasis is commonly found in immuno-compromised patients, including HIV
and cancer patients, and in other chronic disease states such as diabetes. For instance,
oropharyngeal candidiasis is the most frequently occurring infection in head and neck
cancer patients undergoing radiation therapy. The clinical presentation of oropharyngeal
candidiasis is variable with symptoms including soreness, burning, and/or altered taste.
The signs of clinical candidiasis usually include white pseudomembraneous plaques and
patches (thrush), erythematous lesions or occasionally angular cheilitis. Left untreated,
the condition may progress to involve the esophagus or to more serious systemic
complications.

About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global
reach. It practises a reduced risk business model by acquiring compounds from, and
bringing compounds into, Japan through exploitation of its unique position within global
markets.

For further information about Sosei, please visit http://www.sosei.com.

About BioAlliance Pharma

Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and
radiotherapy-induced complications and opportunistic infections in immunocompromised
patients – BioAlliance conceives and develops innovative products, especially in the
hospital setting and for orphan or rare diseases.

For more information, visit the BioAlliance Pharma web site at

http://www.bioalliancepharma.com.

SOURCE Sosei Group Corporation


Source: PR Newswire